Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Cash from Financing Activities (2016 - 2025)

Perspective Therapeutics (CATX) has disclosed Cash from Financing Activities for 15 consecutive years, with -$13000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 103.77% to -$13000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.3 million through Dec 2025, down 96.44% year-over-year, with the annual reading at $10.3 million for FY2025, 96.44% down from the prior year.
  • Cash from Financing Activities hit -$13000.0 in Q4 2025 for Perspective Therapeutics, down from $213000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $166.3 million in Q1 2024 to a low of -$80000.0 in Q1 2023.
  • Historically, Cash from Financing Activities has averaged $22.3 million across 5 years, with a median of $279000.0 in 2024.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 208010.0% in 2024 and later plummeted 103.77% in 2025.
  • Year by year, Cash from Financing Activities stood at $28000.0 in 2021, then changed by 0.0% to $28000.0 in 2022, then surged by 1157.14% to $352000.0 in 2023, then fell by 1.99% to $345000.0 in 2024, then tumbled by 103.77% to -$13000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for CATX at -$13000.0 in Q4 2025, $213000.0 in Q3 2025, and $132000.0 in Q2 2025.